Switch to:
Also traded in: Austria, Germany, Israel, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.02
NAS:MYL's Cash-to-Debt is ranked lower than
98% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. NAS:MYL: 0.02 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:MYL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 3.45 Max: 49.83
Current: 0.02
0.02
49.83
Equity-to-Asset 0.37
NAS:MYL's Equity-to-Asset is ranked lower than
82% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:MYL: 0.37 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:MYL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.81 Max: 0.94
Current: 0.37
0.19
0.94
Debt-to-Equity 1.21
NAS:MYL's Debt-to-Equity is ranked lower than
88% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. NAS:MYL: 1.21 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:MYL' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.05 Max: 2.73
Current: 1.21
0.01
2.73
Debt-to-EBITDA 4.86
NAS:MYL's Debt-to-EBITDA is ranked lower than
78% of the 495 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.92 vs. NAS:MYL: 4.86 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:MYL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 3.22  Med: 4.72 Max: 7.4
Current: 4.86
3.22
7.4
Interest Coverage 2.01
NAS:MYL's Interest Coverage is ranked lower than
91% of the 648 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 86.08 vs. NAS:MYL: 2.01 )
Ranked among companies with meaningful Interest Coverage only.
NAS:MYL' s Interest Coverage Range Over the Past 10 Years
Min: 1.96  Med: 3.08 Max: 4.02
Current: 2.01
1.96
4.02
Piotroski F-Score: 5
Altman Z-Score: 1.33
Beneish M-Score: -2.71
WACC vs ROIC
9.07%
3.33%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 9.12
NAS:MYL's Operating Margin % is ranked higher than
53% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.97 vs. NAS:MYL: 9.12 )
Ranked among companies with meaningful Operating Margin % only.
NAS:MYL' s Operating Margin % Range Over the Past 10 Years
Min: 9.12  Med: 15.14 Max: 17.19
Current: 9.12
9.12
17.19
Net Margin % 3.90
NAS:MYL's Net Margin % is ranked lower than
56% of the 802 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.32 vs. NAS:MYL: 3.90 )
Ranked among companies with meaningful Net Margin % only.
NAS:MYL' s Net Margin % Range Over the Past 10 Years
Min: -3.53  Med: 7.55 Max: 12.04
Current: 3.9
-3.53
12.04
ROE % 3.53
NAS:MYL's ROE % is ranked lower than
57% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.94 vs. NAS:MYL: 3.53 )
Ranked among companies with meaningful ROE % only.
NAS:MYL' s ROE % Range Over the Past 10 Years
Min: -14.72  Med: 9.83 Max: 29.99
Current: 3.53
-14.72
29.99
ROA % 1.30
NAS:MYL's ROA % is ranked lower than
58% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. NAS:MYL: 1.30 )
Ranked among companies with meaningful ROA % only.
NAS:MYL' s ROA % Range Over the Past 10 Years
Min: -2.47  Med: 3.77 Max: 5.97
Current: 1.3
-2.47
5.97
ROC (Joel Greenblatt) % 22.45
NAS:MYL's ROC (Joel Greenblatt) % is ranked higher than
68% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.23 vs. NAS:MYL: 22.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:MYL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 13.86  Med: 28.81 Max: 38.2
Current: 22.45
13.86
38.2
3-Year Revenue Growth Rate 4.60
NAS:MYL's 3-Year Revenue Growth Rate is ranked lower than
54% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. NAS:MYL: 4.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:MYL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6.1  Med: 15.2 Max: 54.5
Current: 4.6
-6.1
54.5
3-Year EBITDA Growth Rate 8.70
NAS:MYL's 3-Year EBITDA Growth Rate is ranked higher than
53% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. NAS:MYL: 8.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:MYL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -18.8  Med: 11.2 Max: 74.7
Current: 8.7
-18.8
74.7
3-Year EPS without NRI Growth Rate -17.80
NAS:MYL's 3-Year EPS without NRI Growth Rate is ranked lower than
83% of the 663 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. NAS:MYL: -17.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:MYL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3.8 Max: 110.4
Current: -17.8
0
110.4
GuruFocus has detected 4 Warning Signs with Mylan NV NAS:MYL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:MYL's 30-Y Financials

Financials (Next Earnings Date: 2018-11-06)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

MYL Guru Trades in Q3 2017

Diamond Hill Capital 15,980 sh (New)
Paul Tudor Jones 44,766 sh (New)
Steven Cohen 1,499,418 sh (+86.83%)
Richard Pzena 22,721,384 sh (+84.13%)
Steven Romick 7,425,690 sh (+17.09%)
First Pacific Advisors 9,469,120 sh (+15.66%)
Vanguard Health Care Fund 29,844,042 sh (+1.87%)
David Einhorn 10,744,307 sh (+0.40%)
Pioneer Investments 35,014 sh (unchged)
Mario Gabelli 14,500 sh (-0.01%)
John Paulson 14,718,600 sh (-7.63%)
Joel Greenblatt 63,497 sh (-92.38%)
» More
Q4 2017

MYL Guru Trades in Q4 2017

Francisco García Paramés 223,489 sh (New)
Leon Cooperman 237,000 sh (New)
Tom Russo 2,540 sh (New)
Pioneer Investments 399,037 sh (+1039.65%)
Joel Greenblatt 311,184 sh (+390.08%)
Steven Cohen 4,016,928 sh (+167.90%)
Diamond Hill Capital 17,383 sh (+8.78%)
First Pacific Advisors 9,509,860 sh (+0.43%)
Steven Romick 7,425,690 sh (unchged)
Vanguard Health Care Fund 29,844,042 sh (unchged)
Paul Tudor Jones Sold Out
Richard Pzena 21,978,042 sh (-3.27%)
David Einhorn 10,182,307 sh (-5.23%)
John Paulson 12,429,000 sh (-15.56%)
Mario Gabelli 6,500 sh (-55.17%)
» More
Q1 2018

MYL Guru Trades in Q1 2018

Jim Simons 1,422,400 sh (New)
Paul Tudor Jones 31,216 sh (New)
Francisco García Paramés 283,793 sh (+26.98%)
Pioneer Investments 420,346 sh (+5.34%)
Steven Romick 7,425,690 sh (unchged)
Vanguard Health Care Fund 29,844,042 sh (unchged)
Mario Gabelli 6,500 sh (unchged)
Tom Russo Sold Out
Leon Cooperman Sold Out
Joel Greenblatt Sold Out
First Pacific Advisors 9,446,830 sh (-0.66%)
Richard Pzena 21,293,375 sh (-3.12%)
John Paulson 11,543,000 sh (-7.13%)
David Einhorn 7,652,000 sh (-24.85%)
Diamond Hill Capital 7,780 sh (-55.24%)
Steven Cohen 1,611,776 sh (-59.88%)
» More
Q2 2018

MYL Guru Trades in Q2 2018

Francisco García Paramés 367,018 sh (+29.33%)
Jim Simons 1,541,013 sh (+8.34%)
Vanguard Health Care Fund 30,606,342 sh (+2.55%)
Steven Romick 7,425,690 sh (unchged)
Mario Gabelli 6,500 sh (unchged)
John Paulson 11,543,000 sh (unchged)
Diamond Hill Capital Sold Out
Paul Tudor Jones Sold Out
First Pacific Advisors 9,369,310 sh (-0.82%)
Richard Pzena 21,115,152 sh (-0.84%)
David Einhorn 6,859,000 sh (-10.36%)
Steven Cohen 1,001,200 sh (-37.88%)
Pioneer Investments 244,354 sh (-41.87%)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2018-06-30 Add 2.55%0.06%$35.37 - $41.86 $ 38.99-1%30,606,342
Richard Pzena 2018-06-30 Reduce -0.84%0.04%$35.37 - $41.86 $ 38.99-1%21,115,152
David Einhorn 2018-06-30 Reduce -10.36%0.82%$35.37 - $41.86 $ 38.99-1%6,859,000
Richard Pzena 2018-03-31 Reduce -3.12%0.14%$38.87 - $47.64 $ 38.99-9%21,293,375
John Paulson 2018-03-31 Reduce -7.13%0.73%$38.87 - $47.64 $ 38.99-9%11,543,000
David Einhorn 2018-03-31 Reduce -24.85%1.95%$38.87 - $47.64 $ 38.99-9%7,652,000
Joel Greenblatt 2018-03-31 Sold Out 0.19%$38.87 - $47.64 $ 38.99-9%0
Leon Cooperman 2018-03-31 Sold Out 0.38%$38.87 - $47.64 $ 38.99-9%0
Richard Pzena 2017-12-31 Reduce -3.27%0.12%$32.39 - $42.31 $ 38.992%21,978,042
John Paulson 2017-12-31 Reduce -15.56%1.3%$32.39 - $42.31 $ 38.992%12,429,000
David Einhorn 2017-12-31 Reduce -5.23%0.28%$32.39 - $42.31 $ 38.992%10,182,307
Joel Greenblatt 2017-12-31 Add 390.08%0.15%$32.39 - $42.31 $ 38.992%311,184
Leon Cooperman 2017-12-31 New Buy0.38%$32.39 - $42.31 $ 38.992%237,000
Mario Gabelli 2017-12-31 Reduce -55.17%$32.39 - $42.31 $ 38.992%6,500
Vanguard Health Care Fund 2017-09-30 Add 1.87%0.04%$29.63 - $39.49 $ 38.9914%29,844,042
Richard Pzena 2017-09-30 Add 84.13%1.72%$29.63 - $39.49 $ 38.9914%22,721,384
John Paulson 2017-09-30 Reduce -7.63%0.64%$29.63 - $39.49 $ 38.9914%14,718,600
David Einhorn 2017-09-30 Add 0.40%0.02%$29.63 - $39.49 $ 38.9914%10,744,307
Joel Greenblatt 2017-09-30 Reduce -92.38%0.42%$29.63 - $39.49 $ 38.9914%63,497
Mario Gabelli 2017-09-30 Reduce -0.01%$29.63 - $39.49 $ 38.9914%14,500
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:TSE:4523, NSE:SUNPHARMA, SHSE:600518, NYSE:TEVA, TSE:4507, SZSE:000538, SHSE:600196, XPAR:IPN, OCSE:LUN, NYSE:PRGO, TSE:4508, SZSE:000963, XSWX:VIFN, SZSE:300122, JSE:APN, SHSE:600332, HKSE:03320, SHSE:600085, TSE:4581, SHSE:600535 » details
Traded in other countries:MYL.Austria, 6MY.Germany, MYL.Israel, MYL1.Switzerland, 0R5P.UK,
Headquarter Location:UK
Mylan NV is a generic pharmaceutical manufacturer which develops, licenses, manufactures, markets and distributes generic, over-the-counter (OTC) products in a variety of dosage forms and therapeutic categories.

Mylan is one of the world's largest generic pharmaceutical manufacturers with operations in the United States, Europe, Asia, Middle East, Africa, and Australia. Generic drug sales constitute approximately 90% of revenue. Remaining sales come from a handful of branded products, primarily epinephrine injector EpiPen. Mylan also owns Matrix, an Indian active pharmaceutical ingredient manufacturer.

Top Ranked Articles about Mylan NV

Mylan and Biocon Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim
Mylan Launches Authorized Generic of Ampyra® Tablets
Mylan and Fujifilm Kyowa Kirin Biologics Receive European Marketing Authorization for Hulio®, Biosimilar Adalimumab
Theravance Biopharma and Mylan Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at the European Respiratory Society International Congress
Mylan Adds to Cardiovascular Portfolio With Launch of First Generic of Brevibloc® Injection in Single-Dose Bags
Theravance Biopharma and Mylan to Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at European Respiratory Society International Congress 2018
Teva’s Recovery Is Just Beginning Despite intense competition, Teva's future does seem bright with a massive corporate restructuring underway, cost cutting and a promising pipeline
Teva Pharmaceuticals (TEVA) is not a company I would typically consider investing in. It was a mere three years ago that it hit an all-time high of $70, only to sink to $11 in November 2017. The decline in stock price correlated with the spike in debt and to many, the glory days of Teva had officially come to an end. Read more...
Wall Street Positive on Friday Autodesk jumps on quarterly results
Stock market indexes were trading in positive territory on Friday after Federal Reserve Chairman Jerome Powell's speech, in which he said the U.S. economy will remain strong. The central bank is expected to increase interest rates in September. Read more...
Mylan Launches First Generic for Adcirca® Tablets
Statement from Mylan's Board of Directors

Ratios

vs
industry
vs
history
PE Ratio 45.34
MYL's PE Ratio is ranked lower than
76% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.77 vs. MYL: 45.34 )
Ranked among companies with meaningful PE Ratio only.
MYL' s PE Ratio Range Over the Past 10 Years
Min: 7.32  Med: 28.36 Max: 112.56
Current: 45.34
7.32
112.56
Forward PE Ratio 7.33
MYL's Forward PE Ratio is ranked higher than
95% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.60 vs. MYL: 7.33 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 45.34
MYL's PE Ratio without NRI is ranked lower than
76% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.20 vs. MYL: 45.34 )
Ranked among companies with meaningful PE Ratio without NRI only.
MYL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 7.32  Med: 28.36 Max: 112.56
Current: 45.34
7.32
112.56
Price-to-Owner-Earnings 21.84
MYL's Price-to-Owner-Earnings is ranked higher than
68% of the 324 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.95 vs. MYL: 21.84 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MYL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.37  Med: 28.23 Max: 310
Current: 21.84
13.37
310
PB Ratio 1.65
MYL's PB Ratio is ranked higher than
74% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. MYL: 1.65 )
Ranked among companies with meaningful PB Ratio only.
MYL' s PB Ratio Range Over the Past 10 Years
Min: 0.64  Med: 2.19 Max: 7.02
Current: 1.65
0.64
7.02
PS Ratio 1.75
MYL's PS Ratio is ranked higher than
71% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MYL: 1.75 )
Ranked among companies with meaningful PS Ratio only.
MYL' s PS Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.72 Max: 3.94
Current: 1.75
0.4
3.94
Price-to-Free-Cash-Flow 18.82
MYL's Price-to-Free-Cash-Flow is ranked higher than
73% of the 298 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.84 vs. MYL: 18.82 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MYL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.82  Med: 19.68 Max: 115.12
Current: 18.82
8.82
115.12
Price-to-Operating-Cash-Flow 9.79
MYL's Price-to-Operating-Cash-Flow is ranked higher than
87% of the 392 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.00 vs. MYL: 9.79 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MYL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.07  Med: 11.31 Max: 40.9
Current: 9.79
6.07
40.9
EV-to-EBIT 32.35
MYL's EV-to-EBIT is ranked lower than
77% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. MYL: 32.35 )
Ranked among companies with meaningful EV-to-EBIT only.
MYL' s EV-to-EBIT Range Over the Past 10 Years
Min: -11.9  Med: 21.25 Max: 74.5
Current: 32.35
-11.9
74.5
EV-to-EBITDA 11.37
MYL's EV-to-EBITDA is ranked higher than
71% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. MYL: 11.37 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -22.6  Med: 11.4 Max: 23.3
Current: 11.37
-22.6
23.3
EV-to-Revenue 2.95
MYL's EV-to-Revenue is ranked higher than
56% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.24 vs. MYL: 2.95 )
Ranked among companies with meaningful EV-to-Revenue only.
MYL' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.5  Med: 2.7 Max: 5.6
Current: 2.95
1.5
5.6
PEG Ratio 7.19
MYL's PEG Ratio is ranked lower than
84% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.93 vs. MYL: 7.19 )
Ranked among companies with meaningful PEG Ratio only.
MYL' s PEG Ratio Range Over the Past 10 Years
Min: 0.96  Med: 3.18 Max: 13.61
Current: 7.19
0.96
13.61
Shiller PE Ratio 29.88
MYL's Shiller PE Ratio is ranked higher than
56% of the 252 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.75 vs. MYL: 29.88 )
Ranked among companies with meaningful Shiller PE Ratio only.
MYL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.48  Med: 83.25 Max: 171.44
Current: 29.88
14.48
171.44
Current Ratio 1.29
MYL's Current Ratio is ranked lower than
77% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. MYL: 1.29 )
Ranked among companies with meaningful Current Ratio only.
MYL' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 4.63 Max: 11.71
Current: 1.29
0.83
11.71
Quick Ratio 0.77
MYL's Quick Ratio is ranked lower than
83% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. MYL: 0.77 )
Ranked among companies with meaningful Quick Ratio only.
MYL' s Quick Ratio Range Over the Past 10 Years
Min: 0.55  Med: 3.39 Max: 8.47
Current: 0.77
0.55
8.47
Days Inventory 129.04
MYL's Days Inventory is ranked lower than
56% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.80 vs. MYL: 129.04 )
Ranked among companies with meaningful Days Inventory only.
MYL' s Days Inventory Range Over the Past 10 Years
Min: 88.95  Med: 132.36 Max: 150.11
Current: 129.04
88.95
150.11
Days Sales Outstanding 87.78
MYL's Days Sales Outstanding is ranked lower than
56% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.76 vs. MYL: 87.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 77.49  Med: 92.32 Max: 110.73
Current: 87.78
77.49
110.73
Days Payable 67.11
MYL's Days Payable is ranked lower than
57% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.32 vs. MYL: 67.11 )
Ranked among companies with meaningful Days Payable only.
MYL' s Days Payable Range Over the Past 10 Years
Min: 62.67  Med: 73.72 Max: 101.21
Current: 67.11
62.67
101.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.80
MYL's 3-Year Average Share Buyback Ratio is ranked lower than
68% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.30 vs. MYL: -11.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MYL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.8  Med: -1.6 Max: 7.4
Current: -11.8
-25.8
7.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.04
MYL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
83% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.11 vs. MYL: 1.04 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MYL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.57 Max: 5.33
Current: 1.04
0.62
5.33
Price-to-Intrinsic-Value-DCF (Earnings Based) 4.24
MYL's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
92% of the 110 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. MYL: 4.24 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
MYL' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.46  Med: 1.78 Max: 7.86
Current: 4.24
0.46
7.86
Price-to-Median-PS-Value 1.01
MYL's Price-to-Median-PS-Value is ranked lower than
52% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.94 vs. MYL: 1.01 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MYL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 2.23 Max: 8.34
Current: 1.01
0.38
8.34
Price-to-Peter-Lynch-Fair-Value 6.34
MYL's Price-to-Peter-Lynch-Fair-Value is ranked lower than
94% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.41 vs. MYL: 6.34 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
MYL' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.67  Med: 1.96 Max: 12.34
Current: 6.34
0.67
12.34
Earnings Yield (Greenblatt) % 3.09
MYL's Earnings Yield (Greenblatt) % is ranked lower than
51% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. MYL: 3.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MYL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -15.9  Med: 4.3 Max: 13.6
Current: 3.09
-15.9
13.6
Forward Rate of Return (Yacktman) % 12.06
MYL's Forward Rate of Return (Yacktman) % is ranked higher than
59% of the 421 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.96 vs. MYL: 12.06 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MYL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.8  Med: 12.9 Max: 24.9
Current: 12.06
7.8
24.9

More Statistics

Revenue (TTM) (Mil) $11,718.80
EPS (TTM) $ 0.86
Beta1.37
Volatility24.35%
52-Week Range $30.69 - 47.82
Shares Outstanding (Mil)515.57

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 11,624 12,329 12,792 12,413
EBIT (Mil $) 2,280 2,689 4,148
EBITDA (Mil $) 3,510 3,867 4,327 4,378
EPS ($) 1.45 2.50 3.64 4.21
EPS without NRI ($) 1.45 2.50 3.64 4.21
EPS Growth Rate
(Future 3Y To 5Y Estimate)
2.68%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}